Outcome of CD20-positive Adult B-cell Acute Lymphoblastic Leukemia and the Impact of Rituximab Therapy
Publication date: September 2020Source: Clinical Lymphoma Myeloma and Leukemia, Volume 20, Issue 9Author(s): Hanan Alduailej, Solaf Kanfar, Khalid Bakhit, Heba Raslan, Arwa Alsaber, Layla Bashawri, Afra Aldayel, Khalid Alanezi
Publication date: Available online 8 October 2020Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Kirill A. Lyapichev, Narittee Sukswai, Evgeniya Angelova, Marian J. Kersh, Sherry Pierce, Marina Konopleva, Nitin Jain, Elias J. Jabbour, Jeffrey L. Jorgensen, Sa A. Wang, L. Jeffrey Medeiros, Joseph D. Khoury, Sergej Konoplev
Publication date: October 2020Source: Clinical Lymphoma Myeloma and Leukemia, Volume 20, Issue 10Author(s): Patrick Stelmach, Klaus Wethmar, Christoph Groth, Daniela V. Wenge, Jörn Albring, Jan-Henrik Mikesch, Christoph Schliemann, Christian Reicherts, Wolfgang E. Berdel, Georg Lenz, Matthias Stelljes
Publication date: Available online 18 September 2020Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Vivek Radhakrishnan, Narendra Agrawal, Bhausaheb Bagal, Ishan Patel
Publication date: Available online 18 September 2020Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Ayşe Pınar Öztürk, Başak Koç, Bülent Zülfikar
Relapsed/Refractory multiple myeloma remains a significant clinical challenge despite a wide array of approved therapeutic agents. Immunotherapy offers an advantage in this setting. Chimeric antigen receptor (CAR) modified T-cells have transformed care for patients with hematological malignancies. CAR-T cells targeting CD-19 B-cell lymphoma cells have shown prominent activity in lymphoma and acute lymphoblastic leukemia (ALL). Recently, the CAR-T cell platform for MM demonstrated therapeutic benefit.
The present study aims to evaluate acute complications and survival rates of childhood acute lymphoblastic leukemia (ALL). We assessed 110 patients treated with 'Children's Oncology Group's protocol between 1999 and 2014. Data of 110 patients (65 Male/45 female) and acute complications of 105 patients were recorded. Forty patients were in the standard-risk group, while 70 were in the high-risk group. Infections were the most common type of complications patients (88.5%), followed by gastrointestinal (27.6%), neurological (26.6%), metabolic/endocrine (15.2%), drug-related hypersensitivity (15.2%), avascular necrosis (12.3%)...
This report describes the first systematic literature review of adult acute lymphoblastic leukemia (ALL) practice from India. The literature is scanty and heterogenous with varied institutional incidence rates, male preponderance, B-ALL predominance, and use of different modified non-contemporaneous regimens from developed countries, with reported outcomes of Complete remission (CR), Relapse, and Overall Survival (OS) as 46.7-91.4%, 24.3-57.1%, and 7-46 months, respectively.
Publication date: Available online 6 August 2020Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Emmanuel Almanza-Huante, Karla Espinosa-Bautista, Juan Rangel-Patiño, Roberta Demichelis-Gómez
Fenntartó kezelési módok felnőttkori rosszindulatú hematológiai betegségekben. Orv Hetil. 2020 Sep;161(38):1623-1628 Authors: Udvardy M Abstract Maintenance therapy has been the strong and standard element of many acute lymphoblastic leukaemia protocols, used much less frequently and systematically in adult oncohematological disorders. The first adult maintenance efforts appeared in follicular and mantle cell lymphoma (mostly monoclonal antibody based), along with an early maintenance effort to prolong the plateau phase of myeloma. For the time being, after a...
era J Abstract The decision to incorporate allogeneic hematopoietic stem cell transplant (allo-HSCT) into front-line therapy in adult acute lymphoblastic leukemia (ALL) should be primarily guided by measurable residual disease (MRD) status and the ALL regimen utilized. While there is no doubt that allo-HSCT benefits patients with poor MRD response after induction or consolidation, the indication of allo-HSCT in cases of good MRD clearance is not clear. As targeted immunotherapies result in high MRD-negative CR rates, early incorporation of these therapies may also prove valuable in reducing the need for HCT in the...